STRO Long Call Strategy
STRO (Sutro Biopharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
STRO (Sutro Biopharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $336.5M, a beta of 1.64 versus the broader market, a 52-week range of 6.7-41.88, average daily share volume of 212K, a public-listing history dating back to 2018, approximately 269 full-time employees. These structural characteristics shape how STRO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.64 indicates STRO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on STRO?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current STRO snapshot
As of May 15, 2026, spot at $39.78, ATM IV 111.00%, IV rank 16.52%, expected move 31.82%. The long call on STRO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on STRO specifically: STRO IV at 111.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a STRO long call, with a market-implied 1-standard-deviation move of approximately 31.82% (roughly $12.66 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated STRO expiries trade a higher absolute premium for lower per-day decay. Position sizing on STRO should anchor to the underlying notional of $39.78 per share and to the trader's directional view on STRO stock.
STRO long call setup
The STRO long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With STRO near $39.78, the first option leg uses a $39.78 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed STRO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 STRO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $39.78 | N/A |
STRO long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
STRO long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on STRO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on STRO
Long calls on STRO express a bullish thesis with defined risk; traders use them ahead of STRO catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
STRO thesis for this long call
The market-implied 1-standard-deviation range for STRO extends from approximately $27.12 on the downside to $52.44 on the upside. A STRO long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current STRO IV rank near 16.52% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on STRO at 111.00%. As a Healthcare name, STRO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to STRO-specific events.
STRO long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. STRO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move STRO alongside the broader basket even when STRO-specific fundamentals are unchanged. Long-premium structures like a long call on STRO are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current STRO chain quotes before placing a trade.
Frequently asked questions
- What is a long call on STRO?
- A long call on STRO is the long call strategy applied to STRO (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With STRO stock trading near $39.78, the strikes shown on this page are snapped to the nearest listed STRO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are STRO long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the STRO long call priced from the end-of-day chain at a 30-day expiry (ATM IV 111.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a STRO long call?
- The breakeven for the STRO long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current STRO market-implied 1-standard-deviation expected move is approximately 31.82%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on STRO?
- Long calls on STRO express a bullish thesis with defined risk; traders use them ahead of STRO catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current STRO implied volatility affect this long call?
- STRO ATM IV is at 111.00% with IV rank near 16.52%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.